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Abstract
Various studies have suggested that a neurotoxic cerebrospinal fluid (CSF) profile could be implicated 
in amyotrophic lateral sclerosis (ALS). Here, we systematically review the evidence for CSF cytotoxicity 
in ALS and explore its clinical correlates. We searched the following databases with no restrictions on 
publication date: PubMed, Embase and Web of Science. All studies that investigated cytotoxicity in 
vitro following exposure to CSF from ALS patients were considered for inclusion. Meta-analysis could 
not be performed, and findings were instead narratively summarised. 28 studies were included in our 
analysis. Both participant characteristics and study conditions including CSF concentration, exposure 
time and culture model varied considerably across studies. Of 22 studies assessing cell viability relative 
to controls, 19 studies reported a significant decrease following exposure to ALS-CSF, while three early 
studies failed to observe any difference. Seven of eight studies evaluating apoptosis observed 
significant increases in the levels of apoptotic markers following exposure to ALS-CSF, with the 
remaining study reporting a qualitative difference. Although five studies investigated the possible 
relationship between CSF cytotoxicity and patient characteristics, such as age, gender and disease 
duration, none demonstrated an association with any of the factors. In conclusion, our analysis 
suggests that CSF cytotoxicity is a feature of sporadic and possibly also of familial forms of ALS. Further 
research is, however, required to better characterise its underlying mechanisms and to establish its 
possible contribution to ALS pathophysiology.
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2Abbreviations
ALS = amyotrophic lateral sclerosis; 
BRISQ = Biospecimen Reporting for Improved Study Quality;
C9ORF72 = chromosome 9 open reading frame 72; 
CAMARADES = Collaborative Approach to Meta-Analysis and Review of Animal Data from 
Experimental Studies; 
CSF = cerebrospinal fluid; 
DAPI = 4’,6-diamidino-2-phenyindole;
DMEM = Dulbecco's Modified Eagle Medium;
fALS = familial amyotrophic lateral sclerosis;
FDA = fluorescein diacetate;
FTD = frontotemporal dementia; 
FUS = fused-in-sarcoma; 
HBSS = Hank's Balanced Salt Solution;
hESC = human embryonic stem cell; 
HNE = 4-hydroxynonenal; 
LDH = lactate dehydrogenase;
MEM = Minimal Essential Medium;
MND = motor neuron disease; 
MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
NSC-34 = mouse spinal cord-neuroblastoma hybrid cell line;
NSE = neuron-specific enolase;
PI = propidium iodide;
PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses;
sALS = sporadic amyotrophic lateral sclerosis;
SOD1 = superoxide dismutase 1; 
TDP-43 = TAR DNA binding protein 43; 
TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labelling;
U251 = human glioma cell line;
VSC 4.1 = cholinergic cAMP-differentiated motor neuron-neuroblastoma hybrid cell line.
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3Introduction
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, fatal neurodegenerative condition, 
characterised by the loss of motor neurons both in the brain and spinal cord, leading to paralysis. 
Sporadic ALS accounts for the majority of cases (about 90%), while the remaining occurrences, in 
which the disease is inherited, are known as familial ALS (Brown and Al-Chalabi, 2017). ALS is 
associated with several genes, for example, C9ORF72, TARDBP, SOD1 and FUS, with some genes also 
contributing to the presence of frontotemporal dementia (FTD). 
Advances made in the last decade have led to a much improved understanding of ALS 
pathophysiology, with various mechanisms apparently involved (Hardiman et al., 2017). These include 
glutamate excitotoxicity, abnormal RNA metabolism, oxidative stress and mitochondrial dysfunction, 
amongst others. Given the involvement of impaired protein homeostasis, ALS, similar to other 
neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, is 
viewed as a proteinopathy, with most cases characterised pathologically by the presence of TDP-43-
containing ubiquinated inclusions (Neumann et al., 2006). One longstanding question, however, 
pertains to the extent to which each of the above processes contributes to the overall 
pathophysiology.
Amongst the many lines of enquiry aiming to address this question, several studies have suggested 
that a neurotoxic cerebrospinal fluid (CSF) profile could be implicated in the disease process (Shaw, 
2002; Matias-Guiu et al., 2010; Sumitha et al., 2019; Tokuda et al., 2019). CSF from ALS patients has 
in fact been shown to exert cytotoxicity in vitro (Tikka et al., 2002; Vijayalakshmi et al., 2009; Barber 
et al., 2011; Sumitha et al., 2019), and to provoke wide-ranging pathology, from neurofilament 
phosphorylation to musculoskeletal changes, when administered in vivo (Shahani et al., 2004; Gomez-
Pinedo et al., 2018; Shanmukha et al., 2018). While the cause of these findings remains unclear, they 
nevertheless suggest the presence of one or more potentially toxic factors in ALS-CSF, with possible 
involvement in disease spread (Smith et al., 2015). Consistent with this possibility, recent in vivo 
evidence also includes pathological changes being observed distant to the CSF infusion site (Gomez-
Pinedo et al., 2018).
A growing body of literature, including various proteomic studies, has helped to demonstrate that CSF 
composition in ALS may be abnormal (Barschke et al., 2017; Blasco et al., 2017; Hayashi et al., 2019). 
This includes findings of raised TDP-43 and neurofilament levels, as well as an altered inflammatory 
profile (Majumder et al., 2018; Schreiber et al., 2018; Gille et al., 2019). Thus, establishing the 
neurotoxicity of ALS-CSF and its possible determinants could open potential avenues for elucidating 
the pathophysiology of ALS. We therefore performed a systematic review of in vitro studies in order 
to review the evidence for CSF cytotoxicity in ALS and also to explore the possible association between 
cytotoxicity and clinical factors, such as patient age and disease duration.
https://mc.manuscriptcentral.com/braincom
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4Materials and methods
This study has been performed according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (Moher et al., 2009).
Search strategy
The following databases were searched on 17 April 2020 to identify relevant studies: PubMed, Embase 
and Web of Science. No restrictions on publication date were applied. Search terms were as follows:
PubMed
(‘amyotrophic lateral sclerosis’ OR ‘ALS’ OR ‘motor neuron’ OR ‘motor neurone’ OR ‘MND’) AND 
(‘cerebrospinal fluid’ OR ‘CSF’)
Embase
(‘amyotrophic lateral sclerosis’ OR ‘ALS’ OR ‘motor neuron’ OR ‘motor neurone’ OR ‘MND’) AND 
(‘cerebrospinal fluid’ OR ‘CSF’)
Web of Science
(‘amyotrophic lateral sclerosis’ OR ‘ALS’ OR ‘motor neuron’ OR ‘motor neurone’ OR ‘MND’) AND 
(‘cerebrospinal fluid’ OR ‘CSF’)
We also reviewed the reference lists of all eligible studies and screened relevant reviews for potential 
citations. We collated all the references obtained from these searches and imported them into 
Endnote X9 for de-duplication. 
Study selection
All studies that investigated cytotoxicity in vitro following exposure to CSF from ALS/MND patients 
were considered for inclusion. Any assay measuring cytotoxicity, cell viability, apoptosis or cell 
proliferation/cell cycle arrest was accepted. No restrictions on cell line were applied. Studies only 
investigating morphological and electrophysiological changes or changes in protein expression levels 
were excluded. In vivo and clinical studies were also excluded. 
Only studies published in a peer-reviewed journal for which full-text articles are available in the English 
language were eligible. Reviews, case reports and conference abstracts were not considered for 
inclusion. Letters to the editor were, however, deemed eligible if sufficient information was provided. 
One author (KCNKK) screened the title and abstract of each paper. For studies meeting the inclusion 
criteria, full-text articles were retrieved and two authors (KCNKK and ARM) independently checked 
the studies for eligibility. 
Data extraction
The primary outcome for this study was in vitro cytotoxicity, while secondary outcomes included the 
clinical correlates of CSF cytotoxicity, namely, the relationship between CSF cytotoxicity and patient 
characteristics including age, gender, disease duration, disease severity, survival time and site of 
onset. Data on these were independently extracted from studies by two authors (KCNKK and ARM). 
https://mc.manuscriptcentral.com/braincom
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5One author (KCNKK) extracted data pertaining to study characteristics, which included the following: 
author, year of publication, country, participant characteristics of both ALS subjects and control 
subjects (including sample size, type of disease, age, gender, disease duration, survival time and site 
of onset), culture model, CSF concentration (v/v%), CSF diluent and presence of serum, exposure time, 
study groups, outcomes assessed, assays for outcome assessment and results.
Quality assessment
Given that no established guidelines currently exist for assessing the quality of in vitro studies, we 
generated a checklist based on modified Collaborative Approach to Meta-Analysis and Review of 
Animal Data from Experimental Studies (CAMARADES) criteria (Macleod et al., 2004; Mehta et al., 
2019), with additional criteria drawn from the Biospecimen Reporting for Improved Study Quality 
(BRISQ) tool (Moore et al., 2011). Each study was assigned an overall quality score (total possible score 
= 9), with one point being given for each of the following: peer-reviewed publication, appropriate 
study approval stated, appropriate control group identified, procurement and maintenance of in vitro 
model described, appropriate description of CSF preservation process, storage temperature of CSF 
provided, blinded assessment of outcome stated, number of replicates performed stated and 
statement of potential conflict of interests. 
Data synthesis
Appropriate summary statistics, including mean difference (MD), standardised mean difference 
(SMD), odds ratio and risk ratio could not be calculated from the extracted data, due to outcome 
measures (such as cell count) not commonly being reported by included studies, as well as 
heterogeneity being observed with respect to the interpretation of results. Thus, although a meta-
analysis was initially planned as part of our analysis, we decided to summarise our results narratively. 
We first tabulated and described study characteristics for all studies, before summarising 
effectiveness results for the different outcomes including cytotoxicity/cell viability and apoptosis. P-
values were calculated where it was possible to confidently do so. The clinical correlates of CSF 
cytotoxicity were also described narratively. 
Data availability statement
All data have been published in this manuscript.
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6Results
We identified a total of 7378 records through database searching which, after de-duplication, reduced 
to 5567 results (Figure 1). After screening of title and abstract, 61 articles remained, of which 33 were 
conference abstracts, in vivo studies or did not report our outcomes of interest, and were therefore 
excluded. Thus, our analysis included 28 studies, conducted across various countries, such as USA, 
France, Japan, India and Spain (Table 1 shows the study characteristics of included studies).
Subject characteristics
The sample size of ALS subjects ranged from 3 to 31, with different ALS patient populations being 
studied, some of which include sporadic ALS, familial ALS, as well as patients with both ALS and FTD. 
Different criteria were also applied to ALS patient selection, since some studies included both subjects 
diagnosed with ‘probable’ and ‘definite’ ALS, while other studies limited participants to those with 
‘definite’ ALS (see Supplementary Table 1 for additional information on participant characteristics 
including: disease description, age, gender, disease duration, survival time and site of onset). Control 
groups varied across studies, and, where possible, we broadly classified them into categories, such as 
‘neurological control’, ‘neurodegenerative control’, ‘non-neurological control’ and ‘non-
neurodegenerative control’. Due to ethical implications, control groups generally did not involve 
healthy individuals. Four studies did not include a control group.
Reporting of subject characteristics, including age, gender, disease duration, survival time and site of 
onset was inconsistent across studies, with the data less likely to be available for earlier studies. In 
studies that reported these, subjects were generally aged between around 45 and 75 years old, while 
gender ratio varied considerably from study to study. The clinical course was either described by 
disease duration or by survival time, although survival times were sometimes inexact in cases where 
some patients were still alive. A number of studies further reported the site of onset, namely, whether 
the disease was limb onset or bulbar onset. Other features that varied across studies include whether 
the subjects were drug-naïve at the time of lumbar puncture and whether age- and gender-matching 
were possible.
Study conditions
Heterogeneity was also observed with regard to study conditions. Different CSF concentrations 
ranging from 1% to 75% were used to assess cytotoxicity, while CSF exposure time also varied from 24 
hours to 21 days. The most common CSF concentration and exposure times, however, were 10% and 
24 hours or 48 hours, respectively. CSF was diluted in culture media such as DMEM in all but two 
studies, where the diluents were HBSS (Terro et al., 1996) and Locke’s solution (Fiszman et al., 2010). 
Serum was present in 17 studies, while eight studies observed serum-free conditions. The presence of 
serum could not be ascertained in the remaining three studies. In vitro culture models included spinal 
cord cultures, cortical neuron cultures and motor neuron cultures, as well as cell lines, such as NSC-34 
(mouse spinal cord-neuroblastoma hybrid cell line), VSC 4.1 (cholinergic cAMP-differentiated motor 
neuron-neuroblastoma hybrid cell line) and U251 cell line (human glioma cell line). One recent study 
also assessed cytotoxicity in motor neurons differentiated from human embryonic stem cells (hESC) 
(Sumitha et al., 2019).
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7Quality assessment
Overall quality score of individual studies ranged from 4 to 8, with lower quality scores generally being 
observed in earlier studies (Supplementary Table 2). Most studies (24 out of 28) included one or more 
control groups. Procurement and maintenance of the in vitro model, as well as CSF preservation and 
storage temperature, were also usually described. Blinded outcome assessment was, however, rarely 
carried out, with only six studies stating that outcomes were blindly assessed.
Cytotoxicity/Cell viability
24 studies assessed cytotoxicity/cell viability through various techniques, including cell counting, 
trypan blue exclusion, MTS assay, MTT assay and LDH assay (Table 2). 19 studies observed a significant 
difference in cell viability following exposure to ALS-CSF compared to controls. The significance level 
across studies varied from p<0.05 to p<0.001, with the p-value not being specified in two studies. In 
one of these studies, however, the difference was only significant at 50% CSF concentration, but not 
at a concentration of 20% (Barber et al., 2011). Another study also failed to observe a decrease in 
neuronal survival at a 24-hour time point, but only reported the difference as significant on day 10 
(Silani et al., 1987). Three early studies did not find any significant difference in cytotoxicity following 
exposure to ALS-CSF compared to controls (Askanas et al., 1981; Swift et al., 1988; Iwasaki et al., 1995). 
Two studies also assessed cytotoxicity within ALS patient populations. In the first study, which 
evaluated CSF cytotoxicity in 31 patients with ‘probable’ or ‘definite’ ALS at the time of diagnosis, 
67.7% of patients were considered to possess cytotoxic CSF, with cytotoxicity being defined as a 
reduction in cell survival greater or equal to 25% compared to control (Galan et al., 2017). The second 
study compared CSF cytotoxicity between sporadic ALS patients with a high concentration of 
4-hydroxynonenal (HNE) with those with a low concentration of HNE, and reported a significant 
difference both at 1% and 10% CSF concentration (Smith et al., 1998). 
Apoptosis
Apoptosis was investigated by eight studies via techniques such as TUNEL assay, caspase-3 assay, 
caspase-9 assay, Bcl-2 assay and Bax assay. Seven of these studies were quantitative in nature and 
observed significant increases in the levels of different apoptotic markers, including caspase-3 and 
caspase-9, following exposure to ALS-CSF compared to controls. However, the increase in Bcl-2 levels 
following ALS-CSF exposure did not reach statistical significance (Ding et al., 2015; Sumitha et al., 
2019) The remaining study, which only qualitatively evaluated apoptosis, reported the presence of 
TUNEL-stained nuclei in cells exposed to ALS-CSF, but not in those from control groups (Vijayalakshmi 
et al., 2011). We also note that ALS-FTD-CSF produced a significant increase in caspase-3 expression 
compared to ALS-CSF, although it was found to result in a significant decrease in Bcl-2 levels (Ding et 
al., 2015).
Clinical correlates
Five studies further assessed the possible relationship between CSF cytotoxicity and patient 
characteristics, including age, disease duration, disease severity, survival time and site of onset (Table 
3). However, none of the studies demonstrated an obvious association between CSF cytotoxicity and 
any of the listed factors. Although one study reported differences based on age, gender and site of 
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8onset, the difference was not statistically significant (Yanez et al., 2011). Another study also reported 
very low apoptotic activity in patients with the longest survival times, but a clear correlation was again 
not established (Barber et al., 2011).
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9Discussion
Our summary of findings in this study suggests that CSF cytotoxicity is a feature of sporadic and also 
possibly of familial ALS, with ALS-CSF appearing to exert cytotoxicity at a wide range of concentrations 
and exposure times, as well as across different culture models. Although a few studies failed to 
observe cytotoxicity following exposure to ALS-CSF compared to controls, we note that these were 
generally earlier studies (Askanas et al., 1981; Silani et al., 1987; Swift et al., 1988; Iwasaki et al., 1995). 
Our results also indicate an apoptotic component to ALS-CSF, with greater apoptosis being observed 
in cells following exposure to CSF from patients with both ALS and FTD (Ding et al., 2015). However, 
we fail to demonstrate a connection between CSF cytotoxicity and patient characteristics, such as age, 
gender, disease duration and survival time. The cause of this lack of association remains unclear, but 
suggests that CSF cytotoxicity may not be appropriate as a biomarker in ALS.
While the findings from this study support the cytotoxicity of ALS-CSF, little consensus exists as to the 
factors underlying it. Different potential candidates have been suggested to explain ALS-CSF 
cytotoxicity, with glutamate being an important example, given the potentially raised glutamate levels 
in ALS patients (Spreux-Varoquaux et al., 2002; Fiszman et al., 2010). However, although glutamate 
antagonists have been shown to have a protective effect on CSF neurotoxicity, less evidence is 
available to support the toxicity of glutamate endogenous to ALS-CSF (Couratier et al., 1994; Tikka et 
al., 2002; Anneser et al., 2006; Matias-Guiu et al., 2010). Riluzole, despite its modest clinical benefit, 
also failed to confer neuroprotection in vitro (Yanez et al., 2011). 
Another potential mechanism underlying CSF-induced neurodegeneration, given the increasing 
recognition of ALS as a proteinopathy and the  growing evidence supporting the prion-like properties 
of several key ALS proteins, notably that of TDP-43 and SOD1 (Brauer et al., 2018), is proteostasis. This 
is supported by findings demonstrating that CSF containing misfolded SOD1 could trigger 
neurodegeneration in NSC-34 cells (Tokuda et al., 2019). Another recent study further revealed that 
ALS-CSF could promote TDP-43 proteinopathy both following in vitro exposure and in vivo injection, 
although the observed changes were much more pronounced in hTDP43 transgenic mice, than in 
normal mice (Mishra et al., 2020). Other ALS proteins that have been suggested to possess prion-like 
properties include FUS and C9ORF72-associated dipeptide repeat proteins (Nomura et al., 2014; 
Westergard et al., 2016), but whether they could exert toxicity at levels comparable to that of ALS-
CSF is unclear.
Consistent with the non-cell autonomous component of ALS pathophysiology (Zhao et al., 2019), ALS-
CSF toxicity was also found to extend to glial cells. Notably, exposure to ALS-CSF has been found to 
result in pro-inflammatory activity, both in astrocytes and microglia (Mishra et al., 2016; Mishra et al., 
2017). Furthermore, ALS-CSF was also found to produce different changes in motor neurons co-
cultured with glia than in motor neuron mono-cultures (Barber et al., 2011), although the reasons for 
this disparity remain to be established. Highlighting the potentially inflammatory aspect of ALS-CSF, a 
number of immune components and growth factors have also been linked to CSF cytotoxicity (Matias-
Guiu et al., 2010). 
Acknowledging that the pathophysiology of ALS remains unknown, characterising cytotoxicity 
associated with ALS-CSF could greatly improve our understanding of the mechanisms responsible for 
neurodegeneration in ALS patients. These insights could arise from additional studies employing a 
proteomic approach, given that few such studies have been performed so far (Varghese et al., 2013). 
In vitro results also need to be complemented by in vivo evidence, which have to date revealed various 
changes following CSF infusion, including neurofilament phosphorylation, endoplasmic reticulum 
stress, as well as motor dysfunction (Deepa et al., 2011; Vijayalakshmi et al., 2011; Shanmukha et al., 
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2018). Although the observed changes have been reported to be histologically similar to sporadic ALS 
cases (Gomez-Pinedo et al., 2018), whether CSF toxicity studies accurately capture the mechanisms 
involved in ALS pathophysiology, and could serve as an important model for ALS, is not yet clear. 
Various lines of evidence, however, hint at a potential contribution of CSF in the spread of the disease 
in ALS patients, with one major appeal for this model being its explanatory potential with respect to 
clinical observations (Smith et al., 2015). 
Indeed, despite numerous models having been posited to explain disease evolution in the context of 
ALS, clinical observations remain incompletely explained. In addition to being highly heterogeneous, 
the disease is occasionally found to spread in a non-contiguous manner, with the onset believed to be 
multifocal in nature (Sekiguchi et al., 2014). Trans-synaptic spread and cell-to-cell transmission via 
exosomes have both been suggested as possible mechanisms of spread (Braak et al., 2013; Iguchi et 
al., 2016). With the evidence for exosome transmission still a topic of debate (Brauer et al., 2018), 
future research aimed at uncovering its possible contribution could play an important role in 
determining the importance of CSF circulation as a route of spread. Necroptosis, in which the contents 
of the dying cell are released into the surrounding environment, is another possible mechanism that 
may deserve investigation (Ito et al., 2016).
Intriguingly, while considerably more literature surrounds CSF cytotoxicity in the context of ALS, this 
does not appear to be a feature specific to ALS. Similar to ALS, the neurotoxicity of CSF from patients 
with Parkinson’s disease patients has been demonstrated as early as 1999, with degeneration of 
dopaminergic neurons being observed in vitro (Le et al., 1999). This finding has also been confirmed 
more recently by a different group (Kong et al., 2015). Furthermore, we also found that, in some of 
the studies included in this review, CSF from control groups could also exert cytotoxicity. For instance, 
one study, in which ALS-CSF cytotoxicity was assessed alongside CSF from ten control subjects 
undergoing lumbar puncture to exclude subarachnoid haemorrhage or viral meningitis, demonstrated 
significantly increased cytotoxicity following exposure to CSF from control subjects compared with 
ALS-CSF (Barber et al., 2011).
Nevertheless, although we consider our findings to be suggestive of the cytotoxicity of ALS-CSF, we 
acknowledge a number of limitations in this review. First, included studies assessed cytotoxicity in 
different cell lines, some of which, including the VSC4.1 and U251 cell lines, could potentially have 
responded differently to CSF exposure compared to motor neurons. The NSC-34 cell line, which has 
been used by many studies to study CSF cytotoxicity has also been subject to controversy in the past 
(Hornburg et al., 2014). Given the qualitative nature of this study, it was not possible to investigate 
the difference in vulnerability between cortical and spinal neurons to CSF cytotoxicity. The variety of 
cell lines employed, some of which could differ considerably from human motor neurons in their 
response to CSF exposure, is also a major limitation of our study. Notwithstanding this, one recent 
study that post-dates our literature search, in which human iPSC-derived spinal motor neurons were 
exposed to ALS-CSF, supports the cytotoxicity of ALS-CSF towards motor neurons (Brauer et al., 2020). 
Second, the considerable heterogeneity with regard to reporting of study results and their 
interpretation meant that we were unable to conduct a meta-analysis. Reporting of study 
characteristics and participant details was also variable, and we therefore failed to further analyse the 
association between patient characteristics and CSF cytotoxicity. Notably, other features of ALS, 
including C9ORF72 status and the presence of cognitive or behaviour change were not commonly 
assessed in study populations, and could therefore be considered in future studies. The time point at 
which lumbar puncture was performed, namely, whether it was part of diagnostic work-up earlier in 
disease trajectory, or later in disease course, was also not always stated. Finally, the contribution of 
study conditions, including CSF concentration and exposure time, could also be more extensively 
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investigated. Although the CSF diluent and the presence of serum did not appear to influence CSF 
cytotoxicity overall, a definite conclusion cannot be drawn.
Moving forwards, we believe that there is a need for future studies assessing CSF cytotoxicity to 
provide an accurate record of study procedures and ensure greater consistency in reporting of study 
results, in order to facilitate meta-analysis of research findings. We thus present a checklist 
(Supplementary Table 3), which, though not intended as a comprehensive guideline, includes items 
of possible relevance to the assessment of CSF cytotoxicity. Disease staging, for instance, despite its 
known association with CSF composition, is not always reported by studies. In particular, we 
recommend that, with respect to study results, steps involved in the calculation of the summary 
statistic, as well as the study groups involved, are clearly described, with the raw data made available 
for possible future analyses.  
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Conclusion
The lack of success in finding a possible treatment for ALS, with the only globally licenced drug for ALS 
so far being riluzole (Bensimon et al., 1994), has led to various lines of enquiry aimed at identifying 
the processes underlying ALS pathophysiology. Here, we performed a qualitative assessment of the 
existing literature, the outcome of which suggests that CSF cytotoxicity, a feature which has previously 
been linked to ALS pathophysiology, can be observed in sporadic and possibly also in familial forms of 
ALS. Thus, improving our understanding of the mechanisms responsible for CSF cytotoxicity, and, 
importantly, establishing their possible contribution in ALS pathophysiology, could play a potential 
role in future ALS research. 
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Figure legends
Figure 1: PRISMA flow diagram. PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) flow diagram describing each stage of the study selection process.
*Quantitative analysis could not be performed due to outcome measures required to calculate 
appropriate summary statistics not commonly being reported by included studies. Results were also 
interpreted differently across studies, and thus could not be pooled together. 
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Table 1. Study characteristics of included studies
Author/s (Year 
of publication)
Country ALS patient population Control subjects Study groups CSF 
concentration 
(v/v%)
CSF 
diluent*
Exposure 
time
Culture model Quality 
score
Askanas et al. 
(1981)
USA 10 patients with ALS 7 neuromuscular 
control patients (NC)
2 non-neuromuscular 
control patients (NNC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Cells exposed to NNC- CSF
- Untreated cells
50%, 75% Culture 
medium
8 days Rat spinal cord 
culture
4
Silani et al. 
(1987)
Italy 3 patients with sporadic ALS 4 control patients 
(Con)
- Cells exposed to ALS-CSF
- Cells exposed to Con-CSF
- Untreated cells
10% DMEM (+) 24 hours Human fetal 
motor cortex 
culture
5
Swift et al. 
(1988)
USA 4 patients with ALS None - Cells exposed to ALS-CSF
- Untreated cells
1.25%, 2.5%, 
5%, 10%, 37.5% 
Culture 
medium
21 days Rat spinal 
motor neuron 
culture
4
Couratier et al. 
(1993)
France 10 patients with ALS 10 neurodegenerative 
control patients (NC)
10 non-
neurodegenerative 
control patients (NNC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Cells exposed to NNC-CSF
- Untreated cells
10%, 20%, 50% MEM 
Earle’s salts 
(+)
24 hours Rat cortical 
neuron culture
5
Couratier et al. 
(1994)
France 8 patients with ALS 8 non-
neurodegenerative 
control patients (NNC)
- Cells exposed to ALS-CSF
- Cells exposed to NNC-CSF
- Untreated cells
50% MEM 
Earle’s salts 
(+)
24 hours Rat cortical 
neuron culture
5
Iwasaki et al. 
(1995)
Japan 10 patients with ALS 10 neurodegenerative 
control patients (NC)
10 non-
neurodegenerative 
control patients (NNC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Cells exposed to NNC-CSF
10%, 25%, 50% DMEM (+) 8 days Rat spinal cord 
culture
5
Terro et al. 
(1996)
France 7 patients with ALS 7 non-
neurodegenerative 
control patients (NNC)
- Cells exposed to ALS-CSF
- Cells exposed to NNC-CSF
- Untreated cells
20% HBSS (+) 48 hours Rat cortical 
neuron culture
5
Smith et al. 
(1998)
USA 13 sporadic ALS patients with 
high CSF HNE levels 
14 sporadic ALS patients with 
low CSF HNE levels
None - Cells exposed to high HNE ALS-
CSF
- Cells exposed to low HNE ALS-
CSF
1%, 10% Culture 
medium
48 hours VSC 4.1 cell line 7
Tikka et al. 
(2002)
Finland 5 ALS patients homozygous for 
the D90A CuZn-SOD mutation
5 patients with familial ALS
16 patients with sporadic ALS
24 neurological 
control patients (NC)
- Cells exposed to D90A ALS-CSF
- Cells exposed to fALS-CSF
- Cells exposed to sALS-CSF
- Cells exposed to NC-CSF
- Untreated cells
25% DMEM (+) 24 hours Rat spinal cord 
culture
8
Sen et al. 
(2005)
India 10 patients with ALS 10 neurological 
control patients (NC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Untreated cells
10% Eagle’s 
MEM (+)
24 hours Rat spinal cord
culture
7
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Anneser et al. 
(2006)
Germany 12 patients with sporadic ALS 6 control patients 
(Con)
- Cells exposed to ALS-CSF
- Cells exposed to Con-CSF
- Untreated cells
10% L-15 
Medium (+)
24 hours Chick motor 
neuron culture 
and chick 
mixed spinal 
cord culture
5
Shobha et al. 
(2007)
India 5 patients with ALS 5 neurological control 
patients (NC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Untreated cells
10% DMEM (-) 48 hours Rat mixed 
spinal cord 
culture
7
Vijayalakshmi 
et al. (2009)
India 5 patients with sporadic ALS 5 neurological control 
patients (NC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Untreated cells
10% DMEM (+) 48 hours NSC-34 cell line 7
Fiszman et al. 
(2010)
Argentina 6 patients with sporadic ALS 3 control patients 
(Con)
- Cells exposed to ALS-CSF
- Cells exposed to Con-CSF
- Untreated cells 
50% Locke’s 
solution (-)
24 hours Mouse cortical 
neuron culture
7
Barber et al. 
(2011)
UK 10 patients with ALS 10 control patients 
(Con)  
- Cells exposed to ALS-CSF
- Cells exposed to Con-CSF
- Untreated cells
20%, 50% Neurobasal
Medium (-)
24 hours Rat motor 
neuron culture
8
Kulshreshtha et 
al. (2011)
India 6 patients with ALS 6 neurological control 
patients (NC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Untreated cells
10% DMEM (+) 48 hours NSC-34 cell line 7
Vijayalakshmi 
et al. (2011)
India 5 patients with sporadic ALS 5 neurological control 
patients (NC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Untreated cells
10% DMEM (+) 48 hours NSC-34 cell line 6
Yanez et al. 
(2011)
Spain 27 patients with ALS 14 control patients 
(Con)
- Cells exposed to ALS-CSF
- Cells exposed to Con-CSF
- Untreated cells
10% Neurobasal 
medium (-)
24 hours Rat cortical 
neuron culture 
8
Varghese et al. 
(2013)
India 16 patients with ALS 13 control patients 
(Con)
- Cells exposed to ALS-CSF
- Cells exposed to Con-CSF
- Untreated cells
10% DMEM (+) 48 hours NSC-34 cell line 8
Gomez-Pinedo 
et al. (2014)
Spain 3 patients with ALS 3 control patients 
(Con)
- Cells exposed to ALS-CSF
- Cells exposed to Con-CSF
- Untreated cells
10% Neurobasal 
medium (-)
24 hours Rat cortical 
neuron culture
7
Yanez et al. 
(2014)
Spain 17 patients with ALS None - Cells exposed to ALS-CSF
- Untreated cells
10% Neurobasal 
medium (-)
24 hours Rat cortical 
neuron culture
4
Ding et al. 
(2015)
China 18 patients with sporadic ALS
8 patients with sporadic ALS 
and FTD
15 non-neurological 
control patients (NNC)
- Cells exposed to ALS-CSF
- Cells exposed to ALS-FTD-CSF
- Cells exposed to NNC-CSF
30% DMEM (+) 21 days U251 cell line 8
Sharma et al. 
(2015)
India 10 patients with ALS 10 control patients 
(Con)
- Cells exposed to ALS-CSF
- Cells exposed to Con-CSF
- Untreated cells
10% DMEM (+) 48 hours NSC-34 cell line 8
Vijayalakshmi 
et al. (2015)
India 5 patients with sporadic ALS 5 neurological control 
patients (NC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Untreated cells
10% DMEM (+) 48 hours NSC-34 cell line 7
Galan et al. 
(2017)
Spain 31 patients with ALS None - Cells exposed to ALS-CSF
- Untreated cells
10% Neurobasal 
medium (-)
24 hours Rat cortical 
neuron culture
7
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Shruthi et al. 
(2017)
India 5 patients with ALS 5 neurological control 
patients (NC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Untreated cells
10% DMEM (+) 48 hours NSC-34 cell line 7
Sumitha et al. 
(2019)
India 5 patients with sporadic ALS 5 neurological control 
patients (NC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Untreated cells
10% DMEM (-) 48 hours hESC-derived 
motor neuron 
culture
7
Tokuda et al. 
(2019)
Japan 10 patients with sporadic ALS
1 patient with familial SOD1-
ALS
15 neurodegenerative 
control patients (NC)
11 non-
neurodegenerative 
control patients (NNC)
- Cells exposed to ALS-CSF
- Cells exposed to NC-CSF
- Cells exposed to NNC-CSF
- Untreated cells
10% DMEM (+) 48 hours NSC-34 cell line 8
*Serum presence and serum-free conditions are indicated in brackets as ‘+’ and ‘-‘ respectively
DMEM: Dulbecco's Modified Eagle Medium
HBSS: Hank's Balanced Salt Solution
hESC: human embryonic stem cell
HNE: 4-hydroxynonenal
MEM: Minimal Essential Medium
NSC-34: mouse spinal cord-neuroblastoma hybrid cell line
U251: human glioma cell line
VSC 4.1: cholinergic cAMP-differentiated motor neuron-neuroblastoma hybrid cell line
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Table 2. Summary of findings of included studies
Author/s (Year of 
publication)
Outcome/s 
assessed
Assay/s for assessing 
outcome
Results
Askanas et al. (1981) Cell viability NSE radioimmunoassay Little evidence for toxic effect of CSF suggested by slight decrease (~9%) in enolase activity of CSF-treated cultures (ALS and disease 
controls) compared with untreated cultures.
Silani et al. (1987) Cell viability NS No obvious decrease in neuronal survival following exposure to ALS-CSF at 24h. Neuronal cell loss only observed at day 5, with 
the decrease becoming significant at day 10.
Swift et al. (1988) Cell viability NS No change in motor neuron survival observed following exposure by ALS-CSF.
Couratier et al. (1993) Cell viability Cell counting Significant decrease in neuronal survival following exposure to 50% ALS-CSF compared to controls (p<0.001). A smaller decrease 
in survival was observed at more dilute ALS-CSF concentrations (20% and 10%).
Couratier et al. (1994) Cell viability Cell counting, FDA staining Significant decrease in neuronal survival following exposure to ALS-CSF compared to controls (p<0.001). 
Iwasaki et al. (1995) Cell viability Cell counting No significant differences in neuronal survival following exposure to ALS-CSF compared to controls at any CSF concentration.
Terro et al. (1996) Cell viability Cell counting, FDA and PI 
double staining
Significant decrease in neuronal survival following exposure to ALS-CSF compared to controls (p<0.001). 
Smith et al. (1998) Cell viability Trypan blue staining, MTS 
assay
Significant difference in VSC 4.1 cell survival between samples exposed to high HNE ALS-CSF and low HNE ALS-CSF both at 1% CSF 
and 10% CSF (p<0.001). 
Tikka et al. (2002) Cell viability, 
apoptosis
Cell counting, bis-benzimide 
staining
Significant increase in the proportion of apoptotic neurons and significant decrease in the percentage of surviving neurons 
following exposure to D90A ALS-CSF, fALS-CSF and sALS-CSF compared to controls (p<0.05). 
Sen et al. (2005) Cell viability Live/dead cell assay (calcein-
AM and ethidium homodimer)
Significant decrease in both motor neuron survival and survival of other spinal neurons following exposure to ALS–CSF compared 
to controls (p<0.001). Significant difference between motor neuron survival compared to survival of other spinal neurons also 
observed (p<0.001).
Anneser et al. (2006) Cell viability, 
apoptosis
Cell counting, trypan blue 
staining, PI/DAPI staining, 
TUNEL assay
Significant increase in apoptotic cells and significant decrease in motor neuron survival following exposure to ALS-CSF compared 
to controls (p<0.001). Significant decrease in survival also observed in mixed spinal cord culture following exposure to ALS-CSF (p-
value not specified).
Shobha et al. (2007) Cell viability LDH assay Increased LDH activity following exposure to ALS-CSF compared to controls (p-value not specified).
Vijayalakshmi et al. 
(2009)
Cell viability MTT assay, LDH assay Significant reduction in viability of NSC-34 cells (p<0.001) and significant increase in LDH activity (p<0.01) following exposure to 
ALS-CSF compared to controls.
Fiszman et al. (2010) Cell viability Cell counting, trypan blue 
staining
Significant decrease in neuronal survival following exposure to ALS-CSF compared to controls (p<0.05).
Barber et al. (2011) Cell viability Cell counting Significant decrease in motor neuron survival following exposure to 50% ALS-CSF (p<0.05) and 50% Con-CSF (p<0.005) compared 
to untreated samples. Decrease in motor neuron survival however not significant at 20% ALS-CSF and 20% Con-CSF.
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Kulshreshtha et al. 
(2011)
Cell viability LDH assay Significant increase in LDH activity following exposure to ALS-CSF compared to controls (p<0.01).
Vijayalakshmi et al. 
(2011)
Apoptosis TUNEL assay TUNEL-positive nuclei observed in cells exposed to ALS-CSF while cells in control groups showed unstained nuclei. 
Yanez et al. (2011) Cell viability MTT assay, LDH assay Significant decrease in neuronal viability (p<0.001) and significant increase in LDH activity (p<0.05) following exposure to ALS-CSF 
compared to controls. 
Varghese et al. (2013) Cell viability MTT assay, LDH assay Significant decrease in cell viability and significant increase in LDH activity following exposure to ALS-CSF compared to controls 
(p<0.001).
Gomez-Pinedo et al. 
(2014)
Apoptosis Caspase-3 assay Significant increase in caspase-3 positive cells following exposure to ALS-CSF compared to controls (p<0.05).
Yanez et al. (2014) Cell viability MTT assay Significant decrease in neuronal viability following exposure to ALS-CSF compared to control (p<0.05).
Ding et al. (2015) Apoptosis Caspase-3 assay, Bcl-2 assay Significant increase in cleaved caspase-3 levels following exposure to ALS-CSF (p<0.05) and ALS-FTD-CSF (p<0.01) compared to 
control. Significant decrease in Bcl-2 levels following exposure to ALS-FTD-CSF compared to both ALS-CSF and control (p<0.05).
Sharma et al. (2015) Cell viability MTT assay Significant decrease in neuronal viability following exposure to ALS-CSF compared to controls (p<0.001).
Vijayalakshmi et al. 
(2015)
Apoptosis TUNEL assay, caspase-3 assay Significant increase in proportion of TUNEL-positive cells and expression of caspase-3 following exposure to ALS-CSF compared to 
controls (p<0.001).
Galan et al. (2017) Cell viability MTT assay CSF cytotoxicity was observed in 21 patients (67.7%) while the remaining 10 patients (32.3%) were considered to possess non-
cytotoxic CSF (Cytotoxicity was defined as a decrease in neuronal viability greater or equal to 25% compared to control)
Shruthi et al. (2017) Cell viability, 
apoptosis
MTT assay, caspase-3 assay Significant decrease in cell viability (p<0.05) and significant increase in caspase-3 expression (p<0.05) following exposure to ALS-
CSF compared to controls.
Sumitha et al. (2019) Cell viability, 
apoptosis
MTT assay, LDH assay, 
caspase-9 assay, Bcl-2 assay, 
Bax assay
Significant decrease in neuronal viability and significant increase in LDH activity following exposure to ALS-CSF compared to 
controls (p<0.001). Non-significant increase in proportion of BCL2-positive neurons but significant increases in proportion of Bax-
positive and caspase-9-positive neurons (p<0.05) following exposure to ALS-CSF compared to controls.
Tokuda et al. (2019) Cell viability Cell Counting Kit-8 Significant decrease in cell viability following exposure to ALS-CSF compared to controls (p<0.01)
DAPI: 4’,6-diamidino-2-phenyindole, diacetate 
FDA: fluorescein diacetate
HNE: 4-hydroxynonenal
LDH: lactate dehydrogenase
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NS: not specified
NSE: neuron-specific enolase 
PI: propidium iodide 
TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling
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Table 3. Clinical correlates of ALS-CSF cytotoxicity
Author/s (Year of publication) Patient characteristic Results
Tikka et al. (2002) Survival time Little correlation observed between CSF cytotoxicity and patient survival time. Considerably lower 
apoptotic activity was however observed in the two patients with the longest survival times. 
Anneser et al. (2006) Age, disease duration Little correlation observed between CSF cytotoxicity and age (r = -0.22) or disease duration prior to 
lumbar puncture (r = -0.24). 
Barber et al. (2011) Age, gender, disease duration Little correlation observed between CSF cytotoxicity and age or disease duration. CSF cytotoxicity was 
also not influenced by gender. 
Yanez et al. (2011) Age, gender, disease duration, disease severity, site of onset Although female patients, younger patients and patients with bulbar onset ALS appeared to possess 
more cytotoxic CSF, the differences did not reach statistical significance. No relationship was also 
observed between CSF cytotoxicity and disease duration or disease severity. 
Galan et al. (2017) Age, gender, disease duration, survival time, site of onset No significant differences were observed between patients with cytotoxic CSF and those with non-
cytotoxic CSF with respect to age, gender, disease duration, survival time or site of onset. 
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 Figure 1: PRISMA flow diagram. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) flow diagram describing each stage of the study selection process. *Quantitative analysis could 
not be performed due to outcome measures required to calculate appropriate summary statistics not 
commonly being reported by included studies. Results were also interpreted differently across studies, and 
thus could not be pooled together. 
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Abbreviated summary Ng Kee Kwong et al.
Systematic review of in vitro evidence suggests that cerebrospinal fluid cytotoxicity is a feature of sporadic and possibly also of familial forms of amyotrophic lateral sclerosis. Further research is, however, required to elucidate the mechanisms underlying its toxicity, and to establish its possible contribution in overall pathophysiology. Downloaded from
 https://academ
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m
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